SeaCrest Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $786K | Sell |
13,634
-2,387
| -15% | -$137K | 0.09% | 199 |
|
|
2026
Q1 | $972K | Sell |
16,021
-2,367
| -13% | -$138K | 0.1% | 194 |
|
|
2025
Q4 | $1.04M | Buy |
18,388
+294
| +2% | +$14.1K | 0.11% | 179 |
|
|
2025
Q3 | $806K | Sell |
18,094
-2,148
| -11% | -$100K | 0.09% | 214 |
|
|
2025
Q2 | $937K | Sell |
20,242
-7,018
| -26% | -$345K | 0.1% | 185 |
|
|
2025
Q1 | $1.66M | Buy |
27,260
+3,159
| +13% | +$184K | 0.19% | 98 |
|
|
2024
Q4 | $1.36M | Buy |
24,101
+2,927
| +14% | +$164K | 0.14% | 132 |
|
|
2024
Q3 | $1.1M | Buy |
21,174
+5,576
| +36% | +$262K | 0.12% | 169 |
|
|
2024
Q2 | $648K | Sell |
15,598
-219
| -1% | -$9.8K | 0.07% | 264 |
|
|
2024
Q1 | $858K | Sell |
15,817
-22,522
| -59% | -$1.15M | 0.1% | 202 |
|
|
2023
Q4 | $2M | Sell |
38,339
-80
| -0.2% | -$4.2K | 0.25% | 77 |
|
|
2023
Q3 | $2.23M | Sell |
38,419
-4,206
| -10% | -$258K | 0.29% | 63 |
|
|
2023
Q2 | $2.73M | Buy |
42,625
+230
| +0.5% | +$15.4K | 0.34% | 51 |
|
|
2023
Q1 | $2.94M | Buy |
42,395
+13
| +0% | +$917 | 0.4% | 46 |
|
|
2022
Q4 | $3.05M | Sell |
42,382
-6,266
| -13% | -$472K | 0.44% | 41 |
|
|
2022
Q3 | $3.46M | Sell |
48,648
-1,473
| -3% | -$107K | 0.52% | 35 |
|
|
2022
Q2 | $3.86M | Buy |
50,121
+2,026
| +4% | +$154K | 0.49% | 32 |
|
|
2022
Q1 | $3.51M | Sell |
48,095
-2,290
| -5% | -$154K | 0.4% | 42 |
|
|
2021
Q4 | $3.14M | Sell |
50,385
-5,559
| -10% | -$326K | 0.34% | 57 |
|
|
2021
Q3 | $3.31M | Buy |
55,944
+13,625
| +32% | +$897K | 0.4% | 50 |
|
|
2021
Q2 | $2.83M | Buy |
42,319
+169
| +0.4% | +$11K | 0.34% | 60 |
|
|
2021
Q1 | $2.66M | Buy |
42,150
+1,748
| +4% | +$109K | 0.35% | 59 |
|
|
2020
Q4 | $2.51M | Sell |
40,402
-680
| -2% | -$41.8K | 0.35% | 58 |
|
|
2020
Q3 | $2.48M | Buy |
41,082
+404
| +1% | +$24.3K | 0.4% | 48 |
|
|
2020
Q2 | $2.39M | Buy |
40,678
+903
| +2% | +$54K | 0.41% | 53 |
|
|
2020
Q1 | $2.22M | Buy |
39,775
+488
| +1% | +$29.8K | 0.48% | 48 |
|
|
2019
Q4 | $2.52M | Buy |
39,287
+4,076
| +12% | +$233K | 0.42% | 52 |
|
|
2019
Q3 | $1.79M | Sell |
35,211
-11,690
| -25% | -$549K | 0.33% | 68 |
|
|
2019
Q2 | $2.13M | Buy |
46,901
+2,055
| +5% | +$95.7K | 0.43% | 53 |
|
|
2019
Q1 | $2.14M | Buy |
44,846
+10,629
| +31% | +$529K | 0.37% | 54 |
|
|
2018
Q4 | $1.78M | Buy |
34,217
+521
| +2% | +$28K | 0.37% | 53 |
|
|
2018
Q3 | $2.09M | Buy |
33,696
+234
| +0.7% | +$13.9K | 0.35% | 52 |
|
|
2018
Q2 | $1.85M | Sell |
33,462
-1,140
| -3% | -$61.6K | 0.33% | 56 |
|
|
2018
Q1 | $2.19M | Buy |
34,602
+638
| +2% | +$41K | 0.4% | 51 |
|
|
2017
Q4 | $2.08M | Buy |
+33,964
| New | +$2.12M | 0.38% | 51 |
|
Other funds holding BMY
AIM
FWIA
DLA
SeaCrest Wealth Management's BMY Position: Q2 2026 in Review
SeaCrest Wealth Management reduced its Bristol-Myers Squibb (BMY) stake by 15% in Q2 2026, selling an estimated $137K and leaving 13,634 shares worth $786K. The position accounts for 0.09% of the portfolio, ranked #199.
SeaCrest Wealth Management first reported a position in BMY in Q4 2017 and has held it in 35 quarters since. The position peaked at $3.86M in Q2 2022. 899 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- SeaCrest Wealth Management held 13,634 shares of Bristol-Myers Squibb worth $786K as of Q2 2026.
- SeaCrest Wealth Management sold 2,387 Bristol-Myers Squibb shares in Q2 2026, an estimated $137K.
- Bristol-Myers Squibb made up 0.09% of SeaCrest Wealth Management's portfolio in Q2 2026, its #199 holding.
- SeaCrest Wealth Management first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 35 quarters since.
- SeaCrest Wealth Management's Bristol-Myers Squibb position peaked at $3.86M in Q2 2022.
- 899 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on SeaCrest Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.